booster vaccines – Page 2 – Communicable Diseases Research

Considerations of CD8 + T Cells for Optimized Vaccine Strategies Against Respiratory Viruses

호흡기 바이러스에 대한 최적화된 백신 전략을 위한 CD8 + T 세포의 고려 사항

Review

Published on 2022-06-152022-09-11
Journal: Frontiers in Immunology
[Category] COVID19(2023년), MERS, SARS, 변종, 진단,

Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates

INO-4800 및 INO-4802를 사용한 프라임-부스트 백신 요법은 비인간 영장류에서 SARS-CoV-2에 대한 면역 반응을 증대 및 확대합니다.

Article

Published on 2022-05-092022-09-11
Journal: Vaccine
[Category] Coronavirus, COVID19(2023년), SARS, 변종, 비임상,

[키워드] ACE2 Antibody Response Antibody responses blocking activity Booster vaccine booster vaccines characterized clinical evaluation COVID-19 DNA DNA vaccine Electroporation evaluated expansion homologous or heterologous immune evasion immune response Immunity immunogenicity INO-4800 Intradermal macaque natural infection Neutralizing pandemic portion question regimen regimens rhesus macaque rhesus macaques SARS-CoV-2 SARS-CoV-2 sequence SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2. shifting Strains Support T cell T cells These data Transmissibility vaccination Vaccine variant variants of concern wild-type SARS-CoV-2 Wuhan-Hu-1
[DOI] 10.1016/j.vaccine.2022.03.060 PMC 바로가기 [Article Type] Article

The Psychological Experience of COVID-19 Vaccination and Its Impact on the Willingness to Receive Booster Vaccines among the Chinese Population: Evidence from a National Cross-Sectional Study

Article

Published on 2022-04-292023-07-09
Journal: International Journal of Environmental Research an
[Category] COVID19(2023년),

[키워드] booster vaccines COVID-19 COVID-19 vaccination psychological experience willingness.
[DOI] 10.3390/ijerph19095464 PMC 바로가기

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

오미크론(B.1.1.529) 변이체에 대한 코로나19 백신 효과

Article

Published on 2022-04-212022-09-11
Journal: The New England Journal of Medicine
[Category] COVID19(2023년), SARS, 변종,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 AstraZeneca B.1.1.529 B.1.617.2 BNT162b2 BNT162b2 vaccine booster booster dose booster vaccines calculated Case-control caused ChAdOx1 ChAdOx1 nCoV-19 Combination Control coronavirus coronavirus disease Coronavirus disease 2019 Course declining delta variant dose doses Effectiveness eligible England immunization investigated Moderna mRNA mRNA-1273 mRNA-1273 booster no effect of BNT162b2 omicron Omicron variant Pfizer-BioNTech Population provided rapid increase recipients security severe acute respiratory syndrome Coronavirus symptomatic disease Vaccine Vaccines variant waned
[DOI] 10.1056/NEJMoa2119451 PMC 바로가기 [Article Type] Article

The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies

ChAdOx1 벡터화 백신 AZD2816은 SARS-CoV-2 베타(B.1.351) 및 전임상 연구에서 우려되는 기타 변이체에 대해 강력한 면역원성을 유도합니다.

Article

Published on 2022-03-012022-09-11
Journal: EBioMedicine
[Category] COVID19(2023년), SARS, 변종,

[키워드] addition animals antibodies AstraZeneca AZD1222 B.1.351 B.1.617.2 Beta binding booster booster dose Booster vaccine booster vaccines caused ChAdOx1 ChAdOx1-vectored vaccine clinical development clinically Course death Delta dose effort expresse funds Gamma hospitalisation Immunity immunogenic increase in induce MRC mutated Mutation nCoV Neutralising Antibodies neutralising antibody new SARS-CoV-2 omicron other variant over P.1 pandemic preclinical study Proteins reduced regimens Research SARS CoV2 SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 virus single dose Spike protein Support T cell T cell response T cells the spike protein Vaccine Vaccines variants variants of concern variants of concern. vectored vaccine virus isolate was measured
[DOI] 10.1016/j.ebiom.2022.103902 PMC 바로가기 [Article Type] Article

Predictors of uncertainty and unwillingness to receive the COVID-19 booster vaccine: An observational study of 22,139 fully vaccinated adults in the UK

Articles

Published on 2022-02-032022-10-30
Journal: The Lancet Regional Health - Europe
[Category] COVID-19,

[키워드] addition administration Adults affected age approved booster booster vaccination Booster vaccine booster vaccines Compliance concerning COVID-19 Covid-19 social study COVID-19 vaccination programme COVID-19 vaccine Critical Evidence examined Factor Factors finding FIVE foundation funding Government groups health condition Health messaging highlight identifying infected with COVID-19 initial Innovation Intention lockdowns Logistic regression network physical poor compliance predict predictor Public receive receiving reported risk second socio-demographic Spread Stress supported the vaccine UCL used data Vaccine hesitancy vaccine refusal virus Wellcome Trust widespread with COVID-19
[DOI] 10.1016/j.lanepe.2022.100317 PMC 바로가기 [Article Type] Articles

Sequential immunization with SARS-CoV-2 RBD vaccine induces potent and broad neutralization against variants in mice

SARS-COV-2 RBD 백신과의 순차적 면역화는 마우스의 변이체에 대한 강력하고 광범위한 중화를 유도한다.

Short Report

Published on 2022-01-042022-09-01
Journal: Virology Journal
[Category] 변종, 진단,

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

영국에서 2 가지 용량의 Chadox1 NCOV-19 또는 BNT162B2에 따른 3 가지 용량 (부스터)으로서 7 개의 코비드 -19 백신의 안전성 및 면역 원성

Clinical Trial

Published on 2021-12-182022-08-13
Journal: Lancet (London, England)
[Category] Fulltext, SARS, 임상,

[키워드] 95% CI Ad26 Ad26.COV2.S adverse event age anti-Spike IgG antibody assigned blinded BNT BNT162b2 booster booster vaccination booster vaccines cellular response Cellular responses ChAd ChAdOx1 ChAdOx1 nCoV-19 Control control group control groups Course COV-BOOST COVID-19 COVID-19 vaccine CureVac CVn CVnCoV dose eligibility criteria ELISA female finding FIVE funding generate geometric mean geometric mean ratio geometric mean ratios GMR GMRs group humoral Humoral and cellular responses immunogenicity individuals initial intention-to-treat population investigated IQR ISRCTN janssen laboratory-confirmed SARS-CoV-2 infection Local m1273 median age MenACWY meningococcal conjugate vaccine Moderna modified intention-to-treat mRNA1273 multicentre neutralising response neutralising responses Novavax NVX NVX-CoV2373 Older Older age outcome Pain participant Participants Pfizer Phase 2 phase 2 trial primary analysis quadrivalent meningococcal conjugate vaccine randomised Randomly ranged reactogenicity referred to Registered Safety SARS-COV-2 infection screened secondary Secondary outcomes Serious Adverse Events Seven spike IgG systemic adverse events the median three group three groups treat treatment allocation Trial Vaccine vaccine availability Valneva Viral viral neutralisation VLA2001 were assessed were blinded white wild-type
[DOI] 10.1016/S0140-6736(21)02717-3 PMC 바로가기 [Article Type] Clinical Trial

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination

델타의 중화 감소 (B.1.617.2) 예방 접종 후 SARS-COV-2 우려 변형

Research Article

Published on 2021-12-022022-08-13
Journal: PLoS Pathogens
[Category] Biochemistry, SARS, 변종, 진단,

[키워드] (Beta accumulation African antibody Antibody titre antigenic antigenic drift antigenic profiles assessment Astra Zeneca Author B.1.351 B.1.617.1 B.1.617.2 bat bats Beta BNT162b2 BNT162b2 vaccines Booster vaccine booster vaccines ChAdOx1 changes in collected COVID-19 COVID19 death decrease decreases Delta delta variant dose effective Effectiveness Efficacy elicited evade expressed facilitate fold Fold changes glycoprotein groups hospitalisation Human human cell human cells humans Immunity India indicated individual Infection Lineage magnitude Mutation neutralisation neutralise Neutralising Antibodies neutralising antibody titres of BNT162b2 Pfizer Pfizer/BioNTech Prevent profile protective immune response pseudoviruses recipient recipients reduced reduction reduction in reductions reductions in required risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2 virus sensitivity sera Severe infection shape significantly higher South South Africa spike glycoprotein spike glycoproteins Spike protein subsequent the spike protein titre vaccinated individuals vaccination Vaccine vaccine efficacy Vaccines variant variant B.1.617.2 variants variants of concern Viral viral variant Viral variants virus Virus spike VOCs while with infection with infections Wuhan Wuhan, China
[DOI] 10.1371/journal.ppat.1010022 PMC 바로가기 [Article Type] Research Article

A Predictive Model for Severe COVID-19 in the Medicare Population: A Tool for Prioritizing Primary and Booster COVID-19 Vaccination

Article

Published on 2021-11-152022-10-28
Journal: Biology
[Category] COVID-19,

[키워드] administration advanced age approach benefit booster vaccines calculated can be used CDC Chemotherapy Chronic kidney disease chronic liver disease chronic obstructive Clinical data Clinical risk factors correlated COVID-19 COVID-19 booster vaccine COVID-19 case COVID-19 hospitalization COVID-19 vaccination COVID-19 vaccine COVID-19 vaccine booster prioritization COVID-19 vaccine prioritization criteria diabete dose End-stage renal disease Factors group Health higher risk Hospitalization identify index individual individuals lack leukemia lung cancer mapped Medicare Medicare population Model multivariate logistic regression obesity Predictive Probability pulmonary disease pulmonary fibrosis pulmonary hypertension random reported risk risk factor risk for severe COVID-19 infection risk stratification severe COVID-19 severe COVID-19 disease severe COVID-19 risk model severe disease simple socio-demographic vaccination Vaccine vaccine immunity vulnerability
[DOI] 10.3390/biology10111185 PMC 바로가기 [Article Type] Article